Funded Grants

Background: Transition from the pediatric to adult health care system is a multi-faceted process that should include medical and psychosocial considerations.

Autism is one of the most prevalent neurodevelopmental disorders in Canada. It has a profound impact on the health, wellness and socioeconomic wellbeing of the patients and their families.

Thousands of Canadian children living with severe physical disability are intellectually capable but unable to move independently.

Family caregivers of people with neurodevelopmental disabilities (NDDs) often experience stress and mental health difficulties (e.g., anxiety, depression)

The demonstration that mature somatic cells can be converted to new, heterologous cell types, now termed “cellular reprogramming”, led to the 2012 Nobel Prize in Physiology or Medicine, and sparked an explosion of studies investigating the therapeutic potential of such an approach.

Aberrant tRNA processing and function has the capacity to exacerbate misfolding of ALS-associated proteins and the ensuing toxicity.

The lifetime risk of developing amyotrophic lateral sclerosis (ALS) is approximately 1 in 350 for men and 1 in 440 for women, making it the most common adult-onset motor neuron disease.

There is a pressing unmet need to develop novel therapies for children with Autism Spectrum Disorder (ASD) and self-injurious behaviours (SIB).

TDP-43 (transactive response DNA-binding protein 43) is one of the few genes highly associated with ALS (amyotrophic lateral sclerosis).

Bipolar Disorder (BD) is a chronic psychiatric illness, ranking in the top 10 causes of disability and mortality worldwide, due to suicide and cardiovascular death.